No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal excretion of unchanged triclabendazole appears to be minimal (<10%), therefore there is little potential for an interaction with emtricitabine and tenofovir due to competition for renal elimination pathways.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking